Insulin Receptor Expression and Activity in the Brains of Nondiabetic Sporadic Alzheimer's Disease Cases by Ho, Lap et al.
Hindawi Publishing Corporation
International Journal of Alzheimer’s Disease
Volume 2012, Article ID 321280, 12 pages
doi:10.1155/2012/321280
Research Article
InsulinReceptor Expression and Activity in the Brains of
NondiabeticSporadicAlzheimer’sDisease Cases
LapHo,1 ShrishailamYemul,1 LindsayKnable,1 Pavel Katsel,2,3 Rudy Zhao,1
Vahram Haroutunian,2,3 andGiulioMariaPasinetti1,2,4
1Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA
2Department of Psychiatry, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA
3Mental Illness Research, Education and Clinical Center, James J. Peters Veteran Aﬀairs Medical Center, 130 West Kingsbridge Road,
Bronx, NY 10468, USA
4Geriatric Research, Education and Clinical Center, James J. Peters Veteran Aﬀairs Medical Center,
130 West Kingsbridge Road, Bronx, NY 10468, USA
Correspondence should be addressed to Giulio Maria Pasinetti, giulio.pasinetti@mssm.edu
Received 12 November 2011; Revised 10 February 2012; Accepted 13 February 2012
Academic Editor: Laura Morelli
Copyright © 2012 Lap Ho et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigated the contents of the insulin receptor-beta subunit (IRβ) and [Tyr1162/1163]-phosphorylated IRβ as surrogate
indices of total IR content and IR activation in postmortem hippocampal formation brain specimens from nondiabetic sporadic
Alzheimer’s disease (AD) cases. We found no signiﬁcant changes in the brain contents of total IRβ or [Tyr1162/1163]-phospho-
rylated IRβ, suggesting normal IR content and activation in the brains of nondiabetic sporadic AD cases. Moreover, total IRβ
and [Tyr1162/1163]-phosphorylated IRβ levels in the hippocampal formation are not correlated with the severity of amyloid
or tau-neuropathology. Exploring the regulation of glycogen synthase kinase 3 (GSK3) α/β, key IR-signaling components, we
observed signiﬁcantly lower levels of total GSK3 α/β in brain specimens from nondiabetic AD cases, suggesting that impaired IR
signaling mechanisms might contribute to the onset and/or progression of AD dementia. Outcomes from our study support the
development of insulin-sensitizing therapeutic strategies to stimulate downstream IR signaling in nondiabetic AD cases.
1.Introduction
Evidence from numerous epidemiological studies indicates
that type 2 diabetes (T2D, a noninsulin-dependent form
of diabetes mellitus) is associated with a two- to three-fold
increase in the relative risk for Alzheimer’s disease (AD),
independent of the risk for vascular dementia [1–9]. Experi-
mental evidence suggests that abnormalities in insulin meta-
bolism under diabetic conditions could mechanistically
inﬂuencetheonsetofADviamodulationofthesynthesisand
degradation of amyloidogenic beta-amyloid (Aβ)p e p t i d e s .
For example, insulin itself may signiﬁcantly promote Aβ
accumulation by accelerating amyloid precursor protein/Aβ
traﬃcking from the trans-Golgi network, a major cellular
site for Aβ generation, to the plasma membrane [10]. More-
over, elevated circulating insulin contents under diabetic
conditions may also promote amyloid accumulation by
directcompetitionwithAβfortheinsulin-degradingenzyme
(IDE), and therefore may limit Aβ degradation by IDE [11,
12].
In addition to the direct roles of insulin and IDE,
accumulatingevidenceshowsthatunderdiabeticconditions,
impairmentsincertaininsulinreceptor-(IR-)responsivecel-
lular signaling pathways might also mechanistically promote
AD-related neuropathology and cognitive deterioration [13–
18]. Building on this observation, a recent hypothesis impli-
cates impaired insulin signaling in the brain as a common
underlying cause of sporadic AD, regardless of diabetic or
nondiabetic status [19].
Cellular insulin signaling is initiated by the coupling of
extracellular insulin with the insulin receptor in the plasma
membrane,whichleadstoIRactivationandsubsequentpro-
motion of cellular IR-signaling processes [20]. Despite the
centralroleofIRactivationincellularIR-signalingprocesses,2 International Journal of Alzheimer’s Disease
there is limited and conﬂicting information available on the
regulation and activity of IR in the brains of sporadic AD
cases. In particular, Fr¨ olich et al. [21] reported signiﬁcantly
increased IR-binding activity in the brains of sporadic AD
cases. In contrast, Steen et al. [19]a n dR i v e r ae ta l .[ 22]
observed that AD is associated with signiﬁcantly reduced IR
contents and “IR activity” (i.e., IR tyrosine phosphorylation)
in the brain. Moloney et al. [23] recently reported no change
in the levels of total IRα and IRβ subunits, but found an
aberrant subcellular distribution of IRα and IRβ in temporal
cortex specimens from cases characterized by severe AD
neuropathology, suggesting the presence of compromised
IR signaling in surviving AD neurons. None of the studies
indicate the diabetic status of the study subjects. A recent
study by Liu et al. [18] reported no change in the total IRβ
subunit level in postmortem frontal cortex specimens from
AD cases without diabetes, but there is little information
given on the criteria by which the absence of diabetes was
determined, and there is no information regarding the acti-
vation status of the insulin receptor.
Accumulating epidemiological and experimental evi-
dence suggests that in the AD brain, impairments in select
cellular signaling pathways associated with (but not neces-
sarilylimitedto)IRsignalingmightmechanisticallypromote
AD phenotypes [2, 3, 6, 7, 14–17]. Among these, impaired
glycogen synthase kinase 3 (GSK3) function in the AD brain
hasbeenconsideredpivotalfordiseasedevelopment[24–27].
GSK3 is a ubiquitously expressed, highly conserved serine/
threonine kinase involved in numerous cellular processes
[28]. There are two mammalian GSK3 isoforms, GSK3α and
GSK3β,w i t hG S K 3 β being particularly abundant in the cen-
tral nervous system. GSK3α and β are constitutively active,
but are inactivated by IR-responsive Akt-mediated phospho-
rylation at [Ser21]-GSK3α and [Ser9]-GSKβ,r e s p e c t i v e l y
[28]. Some studies argue that overactivity of GSK3 plays a
critical role in the pathogenesis of both sporadic and fami-
lial AD (for review, see [29]). Accordingly, GSK3 hyperactiv-
ity may contribute to AD by increasing tau hyperphosphory-
lation, promoting Aβ production, and/or stimulating brain
inﬂammatory responses [29]. However, contrary to this
hypothesis there are studies that show evidence of reduced
total GSK3 contents and activity in the AD brain [24, 25]. In
p a r t i c u l a r ,as t u d yb yB a u me ta l .[ 24] revealed signiﬁcantly
reduced contents of total (nonphosphorylated (active) and
phosphorylated (inactive)) GSK3α and GSK3β in the AD
brain. A second study by Griﬃn et al. [25] observed signi-
ﬁcantly reduced contents of GSK3β, coupled with a signif-
icantly elevated ratio of ser9-phospho-GSK3β/total GSK3β,
implicating inactivation of GSK3β in AD compared to con-
trolbrainspecimens.Noneofthestudiesontheregulationof
GSK3intheADbrainindicatethediabeticstatusofthestudy
subjects. In a more recent paper, Liu et al. [18]r e p o r t e dn o
signiﬁcant change in total GSK3β or phosphorylated GSK3β
proteinlevelsinthebrainsofnondiabetic,sporadicADcases.
While T2D is a risk factor for AD, there is little informa-
tion available on the regulation and activity of IR in the AD
brain, either in the absence or in the presence of comorbid
diabetic conditions. IR is a tetrameric transmembrane
receptor comprised of two α and two β subunits [30]. Insulin
binding to IR leads to rapid autophosphorylation of speciﬁc
tyrosine residues in the IRβ subunit, which converts IRβ into
a catalytic active conformation that is necessary for IR signal
transduction [30]. For example, IRβ autophosphorylation at
Tyr1162/1163 is critical for stabilizing IRβ in a catalytically
active conformation [31]. The present study was designed
to explore the regulation of IR contents and IR activation
in the brains of nondiabetic AD cases. We assessed the con-
tents of total (nonphosphorylated and phosphorylated) IRβ
and[Tyr1162/1163]-phosphorylatedIRβassurrogateindices
o f ,r e s p e c t i v e l y ,t o t a lI Rc o n t e n ta n dI Ra c t i v a t i o ni nt h e
brains of nondiabetic AD cases as a function of clinical
AD dementia and AD neuropathology. Results from our
studies demonstrated that there is no detectable change in IR
content and activation in the brain. Nonetheless, we found
signiﬁcantly lower levels of total GSK3β protein in the brains
of nondiabetic AD cases, suggesting that impaired IR sig-
naling mechanisms might contribute to the onset and/or
progression of AD dementia in the absence of diabetes.
2.MaterialsandMethods
2.1. Evaluating the Impact of Postmortem Interval on the
Detection of Phosphorylated IRβ in Mouse Brain Specimens.
Mice were sacriﬁced by cervical dislocation and freshly
isolated brain specimens were either immediately frozen or
stored postmortem for up to 6 hours at room temperature
before homogenization for analysis of total and phospho-
rylated IRβ contents. Tissue specimens were homogenized
in Tris/Triton solution: 250mM sucrose, 50mM Tris-HCl
(pH 7.4), 1mM EDTA, 2mM EGTA, 1% Triton X100 con-
taining 1mM PMSF and cocktails of proteinase/phosphatase
inhibitors(PierceBiotechInc,Rockford,IL,USA).Totalpro-
teinconcentrationinthetissuehomogenateswasdetermined
with a CBQCA Quantitation Kit (Molecular Probes Inc,
Eugene, OR, USA). Aliquot samples of total protein contents
(15μg) were loaded in triplicates onto pre-cast 8% Precise
protein gels (Pierce Biotech Inc, Rockford, IL, USA) under
reducing conditions. Electrophoresis and transblotting were
performed under standard conditions. Total (nonphos-
phorylated and phosphorylated) IRβ and phosphorylated
IRβ were detected, respectively, using mouse monoclonal
L55B10antibodiesfortotalIRβ andrabbitmonoclonal19H7
antibodies for [Tyr 1150/1151]-phosphorylated IRβ;b o t h
antibody preparations were obtained from Cell Signaling
Technology Inc. (Danvers, MA). Image detection was con-
ducted using infrared ﬂuorescence detection (IRDye 680 or
800 goat antiappropriate species IgG, Li-Cor Biosciences,
Lincoln, NE, USA) and scanned using the Odyssey Infrared
Imaging System (Li-Cor Biosciences, Lincoln, NE, USA).
Images were analyzed and quantiﬁed using Odyssey software
ver.3 (Li-Cor Biosciences, Lincoln, NE, USA).
2.2.PatientSelectionCriteria. Human postmortem temporal
muscle and hippocampal formation specimens from AD
and age-matched non-AD cases were obtained from the
Alzheimer’s Disease Brain Bank of the Mount Sinai School
of Medicine [32]. The cases selected had no signiﬁcant
neuropathological features or had only neuropathologicalInternational Journal of Alzheimer’s Disease 3
features associated with AD [32, 33]. Cognitive status of the
cases was assessed based on the cognitive dementia rating
(CDR), which is generated using a multistep evaluation of
cognitive and functional status during the last 6 months of
life, as previously reported [34]. Moreover, only nondiabet-
ic cases were selected for this study; cases with a premorbid
historyofdiabeteswereexcluded.Diabetic(T2D)ornondia-
betic cases were identiﬁed using criteria previously described
[35, 36]. Our analysis included only cases with no record
of diabetes (absence of reported history and failure to meet
blood chemistry-based criteria); cases with a premorbid
history of diabetes were excluded (i.e., plasma glucose con-
centration >200mg/dL, fasting glucose >126mg/dL, 2-hour
plasma glucose > 200mg/dL during oral glucose test, and
impairedfastingglucosewasdeﬁnedas110–125mg/dL(6.1–
7.0mmol/L)).
Tissue samples were divided into groups based on their
CDR categories as follows. CDR 0: cognitive normal (n =
10); CDR 0.5, at high risk of developing AD dementia (n =
9); CDR 1, mild AD dementia (n = 11); CDR 2, moderate
AD dementia (n = 13); CDR 5, severe AD dementia (n =
19).
2.3. Beta-Amyloid and Neuroﬁbrillary Tangle Neuropathology
Assessments in Human Brain Specimens. The extent of neu-
ritic plaque (NP) and neuroﬁbrillary tangles (NFTs) staining
in the brain (entorhinal cortex) was assessed in accord with
the consortium to establish a registry for Alzheimer’s disease
(CERAD) neuropathologic battery [37]. The density of NPs
and NFTs were rated on a 4-point scale: 0, absent; 1, sparse;
3, moderate, and 5, severe. NPs were visualized after either
Bielschowsky silver or thioﬂavin-S staining [38]. Multiple
(∼5) high power (×200, 0.5-mm) ﬁelds were examined in
each histological slide from multiple regions according to
the CERAD regional sampling scheme. All investigators were
masked to the clinical diagnosis of each case until all histo-
logical and biochemical analyses were completed and values
were assigned to each specimen.
The contents of Aβ1–40 and Aβ1–42 in the hippocam-
pal formation were assessed as previously described [39].
Brieﬂy, frozen tissue samples were homogenized in a buﬀer
containing 70% formic acid and 100mmol/L betaine, and
soluble Aβ1–40 and Aβ1–42 were quantiﬁed by enzyme-linked
immunosorbent assays (ELISAs) using, respectively, syn-
thetic Aβ1–40 and Aβ1–42 (US Peptides, Fullerton, CA, USA)
as standards. Microtiter plates were coated with 2mg/mL
monoclonal antibody 4G8 (Senetek, Maryland Heights, MO,
USA), which recognizes an epitope between residues 17 and
20 of Aβ. Unoccupied binding sites on the plates were block-
ed by incubation with casein. Samples and standards were
applied in quadruplicate and incubated for 48 hours at 4◦C.
After the Aβ1–40 and Aβ1–42 capture phase, the plates were
probed with, respectively, an Aβ1–40 or an Aβ1–42 C-terminal-
speciﬁc antibody, followed by incubation with a reporter
antibody (alkaline phosphatase-conjugated anti-rabbit IgG,
γ-chain-speciﬁc)(JBLScientiﬁc,SanLuisObispo,CA,USA).
The assay was developed using an alkaline phosphatase
substrate (Attophos; JBL Scientiﬁc), yielding a ﬂuorescent
product, and analyzed with a 96-well ﬂuorescence reader
(CytoFluor; Millipore, Bedford, MA, USA). All samples were
analyzed in the linear range of the ELISA.
2.4. Regulation of Total IRβ Expression and [Tyr1162/1163]-
IRβ Phosphorylation in Human Brain or Temporal Muscle
Specimens. Frozen banked tissue (hippocampal formation
or temporal muscle) specimens were powderized under
liquid nitrogen and were then homogenized in ice-cold
cell lysis buﬀer (20m Tris/HCl, pH7.5, 150mM NaCl,
1mM ECTA, 1mM EGTA, 1% Triton X-100, 2.5mM
sodium pyrophosphate, 1mM beta-glycerophosphate, 1mM
Na3VO4,1ug/mLleupeptinand1mMphenylsulphonylﬂu-
oride) using a hand held BioVortexer or Pellet Pestle Motor
(Kontes, Northbrook, IL, USA) as previously described [14,
39]. The homogenates were sonicated three times for 10 sec-
onds each (Sonic Dismembrator Model 500, Fisher Scien-
tiﬁc) and were then centrifuged at 13,000xg for 15min. Sup-
ernatants were collected and protein concentrations were
determined using Bradford protein assays (Bio-Rad labora-
tories, Hercules, CA, USA). Supernatants (lysates) were stor-
ed at −80◦C until further analysis.
Total IRβ protein content was quantiﬁed by Western blot
analysis. Protein extracts (25μg) were separated on 10%
SDS-PAGE under reducing conditions and transferred to
PVDF membranes using 10mM CAPS pH11, 10% meth-
anol at 4◦C. The membranes were blocked with 5% block-
ing grade nonfat dry milk in 10mM Tris/HCl pH7.6,
140mM NaCl, 0.1% Tween-20, before being incubated with
a primary anti-IRβ antibody (rabbit polyclonal IgG, C-
19, 1:500 dilution; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Membranes were washed and incubated
with an HRP-conjugated secondary antibody, washed, and
bands were detected using chemiluminescence methodology
(Amersham ECL plus western blotting detection system, GE
Healthcare, UK) followed by exposure to Kodak X-ray ﬁlms.
Films were scanned and appropriate protein band densities
were quantiﬁed with Bio-Rad Quantity-One software (Bio-
Rad laboratories, Hercules, CA, USA). Assessment of β-
actin content using a rabbit polyclonal anti-β-actin antibody
(Sigma, St. Louis, MO, USA) on the same blots served as a
loading control.
Assessmentsof[Tyr1162/1163]-phosphorylatedIRβpro-
tein contents were conducted using a commercial sandwich
[Tyr1162/1163]-phosphorylatedIRβELISAassay(BioSource
International, Inc., Camarillo, CA, USA) that is speciﬁc for
IRβ and does not cross-react with IGF-1Rβ. In this study,
the [Tyr1162/1163]-phosphorylated IRβ ELISA was con-
ducted according to the manufacturer’srecommendations. A
lyophilized lysate from insulin-stimulated human IR trans-
fected Chinese hamster ovary cells provided by the manu-
facturer served as a quantitative standard; 1 unit of standard
is equivalent to the amount of IR [Tyr1162/1163] derived
from 0.6ηgo fI R( β-subunit) in transfected Chinese hamster
ovary cells stimulated with 100nM insulin.
2.5.RegulationofGSK3α/β ExpressioninHumanBrainSpeci-
mens. Contents of total GSK3 α/β [including both phospho-
rylated (inactive) and nonphosphorylated (active) forms] in
hippocampal formation specimens were assessed by western4 International Journal of Alzheimer’s Disease
Table 1: Characteristics of study subjects1.
No. of Mean ± SEM Mean ± SEM Median CERAD Median CERAD
CDR Score subjects Postmortem interval, h Age, y Female, % Plague rating Tangle rating
01 0 5 .44 ±0.91 80.40 ±6.02 70% 0 0
0.5 9 4.30 ±0.40 87.33 ±2.59 67% 3 0
11 1 4 .63 ±0.69 85.00 ±3.33 55% 3 0
21 3 4 .89 ±0.87 87.08 ±1.92 85% 5 3
51 9 4 .82 ±0.72 83.06 ±2.37 74% 5 3
1Only nondiabetic cases are selected for this study; cases with a premorbid history of diabetes are excluded. Subjects are grouped by Clinical Dementia rating
(CDR). Neuropathology is assessed using Consortium to Establish A Registry for Alzheimer’s Disease (CERAD) ratings. Age and postmortem interval (PMI)
are in years.
blot. In this study, 25μg of lysate proteins was assayed using
a commercial anti-GSK3 α/β antibody (mouse monoclonal
1H8 antibody, dilution 1:3,500; Calbiochem, San Diego,
CA, USA) that simultaneously detects total GSK3α and total
GSK3β (inactive phosphorylated and active nonphosphory-
lated GSK3 α/β); identiﬁcation of GSK3α and GSK3β is
basedontheiruniquemolecularsizes:51kDaforGSK3αand
47kDa for GSK3β.
2.6. Statistics. Statistical analysis was performed using the
Prism software package (GraphPad Software, Inc, San Diego,
CA, USA). Analysis of variance (ANOVA) was used to evalu-
ate diﬀerences in mean values among three or more groups,
and the Dunnett t-test was used to test the signiﬁcance of the
diﬀerences in means. One-tailed t-tests were used as indi-
cated. Correlation analysis between two variables was done
using the Pearson parametric method followed by 2-way
analysis of the P value.
3. Results
3.1. Patient Populations. Patient information including age,
postmortem interval, gender, and neuropathological ﬁnd-
ings for cases assessed in this study is summarized in
Table 1. Only nondiabetic cases were selected for this study;
cases with a premorbid history of diabetes were excluded.
Analysis of variance indicated that there were no signiﬁcant
diﬀerences among the CDR groups with respect to age (P =
.40) and postmortem interval (P = .82) at the time of death.
3.2. Evaluating the Potential Impact of Postmortem Interval
on the Detection of Phosphorylated IRβ. Postmortem interval
(PMI) is known to aﬀect the phosphorylation status of a
number of signaling proteins. For example, Li et al. [40]
examined a number of signaling proteins, such as ERK, JNK,
RSK, CREB, and ATF-2 proteins, in mouse brain specimens
at 0, 8, 24, and 48hrs postmortem, and demonstrated dra-
matically reduced contents of phosphorylated species for
each of these proteins by 8hrs postmortem. The cohort of
62 nondiabetic cases selected for our present study were cha-
racterized by a relatively shorter than average postmortem
interval, ranging from a minimal average postmortem inter-
val of 4.3 ± 0.4h for the CDR 0.5 cases to a maximal aver-
age postmortem interval of 5.44 ± 0.91h for the CDR 0
cases (Table 1). In a series of control studies using mouse
brain specimens, we explored the potential impact of simi-
larly short postmortem intervals on the detection of tyrosine
phosphorylated IRβ in brain specimens. We dissected mouse
brain tissue and assessed [Tyr1150/1151]-phosphorylated
IRβ contents from tissue specimens kept at room temper-
ature and found no signiﬁcant changes in the detection of
tyrosine phosphorylated IRβ levels (normalized to total IRβ)
from mouse brain specimens that were kept at room tem-
perature for up to 6hrs postmortem (Figure 1). This sug-
gests that the relatively short postmortem intervals that are
associated with the human brain specimens used in our pre-
sent study likely have no appreciable impact on the detection
of tyrosine-phosphorylated IRβ contents from these speci-
mens.
3.3. Assessment of Total IRβ and [Tyr1162/1163]-Phos-
phorylated IRβ Contents in the Periphery and in the Brain.
We assessed temporal muscle and hippocampal formation
specimens from the same cases to explore the regulation of
IRintheperipheryandinthebrainamongnondiabeticcases
across CDRs. In these studies, Total IR content was assessed
by Western blot analysis of total IRβ peptide contents using
a speciﬁc antibody that does not cross-react with IGF-
1Rβ. The content of [Tyr1162/1163]-phosphorylated IRβ,
assessed using a speciﬁc ELISA that does not cross-react with
IGF-1Rβ, was used as a surrogate index of IR activation.
Consistentwiththeselectionofnondiabeticcasesforthis
study, we found no diﬀerence in the contents of total IRβ
(Figure 2(a); ANOVA, P = .976) and [Tyr1162/1163]-phos-
phorylated IRβ (Figure 2(b); ANOVA, P = .478) in periph-
eral temporal muscle across the CDR groups. Interestingly,
comparable ﬁndings were also observed in the brains of
nondiabetic AD cases. We found no signiﬁcant diﬀerence in
thecontentsoftotalIRβ(Figure 2(c);ANOVA,P = .220)and
[Tyr1162/1163]-phosphorylated IRβ (Figure 2(d); ANOVA,
P = .425) in the hippocampal formation across the CDR
groups among the nondiabetic cases assessed in this study.
3.4. Lack of Correlation between Total IRβ and [Tyr1162/
1163]-Phosphorylated IRβ Contents in the Hippocampal
Formation and AD Neuropathology. We continued to
explore potential interrelationships between total IR and
[Tyr1162/1163]-phosphorylated IRβ contents in the brain
and AD neuropathology among the nondiabetic cases.
We found no correlation between total IRβ content andInternational Journal of Alzheimer’s Disease 5
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Figure 1: Stability of phosphorylated IRβ in mouse brain specimens as a function of postmortem interval. Mice were sacriﬁced and brain
specimens were isolated immediately. Freshly isolated mouse brain specimens were either rapidly frozen or were kept at room temperature
for up to a 6hr postmortem interval. Samples were assessed at 2hr postmortem intervals as indicated. Bar graphs represent the ratio of
[Tyr1150/1151]-phosphorylated IRβ/total IRβ as mean ± SEM values. ANOVA; P = .531; Inset: representative western blot analysis of
[Tyr1150/1151]-phosphorylated IRβ and total IRβ at diﬀerent postmortem time intervals as indicated.
the contents of Aβ1–42 (Figure 3(a); P = .205) or Aβ1–40
(Figure 3(b); P = .271) peptides in the hippocampal forma-
tion. More importantly, we found that the content of
[Tyr1162/1163]-phosphorylated IRβ in the hippocampal
formation is not correlated with the contents of Aβ1–42
(Figure 3(c); P = .684) or Aβ1–40 (Figure 3(d); P = .681)
peptides.
Consistent with our observation that AD-dementia in
nondiabeticcasesisnotassociatedwithsigniﬁcantchangesin
the contents of total IRβ or [Tyr1162/1163]-phosphorylated
IRβ in the brain (Figures 2(c)-2(d)), we found that total or
[Tyr1162/1163]-phosphorylated IRβ contents are not cor-
related with AD-type amyloid neuritic plaque (NP) or
neuroﬁbrillary tangle (NFT) neuropathology in the brain
(Figures 4(a)–4(d)). In particular, based on histological
assessments of neuritic plaques and neuroﬁbrillary tangles
using the 4-point CERAD rating, we found no correlation
between the content of total IRβ in the hippocampal
formation and either NPs (Figure 4(a); P = .749) or NFTs
(Figure 4(c); P = .516). Similarly, we found no correlation
betweenthecontentsof[Tyr1162/1163]-phosphorylatedIRβ
in the hippocampal formation and either NPs (Figure 4(b);
P = .283) or NFTs (Figure 4(d); P = .912).
3.5. Assessment of IR-Associated Molecular Signaling in the
AD Brain. Numerous studies have documented changes in
IR-responsive cellular signaling pathways in the brain. For
example, data has shown reduced GSK3 α and β contents
and activities [24, 25] in the AD brain. Consistent with these
observations, we observed signiﬁcantly lower contents of
total GSK3α (Figure 5(a); P<. 05) and GSK3β (Figure 5(b);
P<. 005) in the hippocampal formation of CDR 1, 2 and 5
cases in comparison to neurological control (CDR 0) cases.
Interestingly, we found no correlation between the con-
tents of [Tyr1162/1163]-phosphorylated IRβ and either total
GSK3α (Figure 4(c); Pearson Correlational analysis, P =
.318) or total GSK3β (Figure 4(d); Pearson Correlation ana-
lysis,P = .308)inthehippocampalformation.Thus,ourevi-
dence suggests that downregulation of total GSK3 α/β con-
tents in the brains of the nondiabetic AD cases analyzed in
this study might be mediated by mechanisms independent of
IR activation.
4. Discussion
Recent hypotheses raised the possibility that impaired IR
signaling in the brain might be a common underlying cause
of sporadic AD [19, 23, 41]. Although cellular IR activation
is the ﬁrst, and a necessary, step in cellular IR-signaling pro-
cesses, there is no consensus on the regulation of IR content
and IR activation in the brains of sporadic AD cases [19, 21,
23]. With the exception of a recent publication by Liu et al.,
[18], it is not known whether any of the AD and control
casesused in previouslyreported studies arecharacterized by
T2D. It is possible that the outcomes in these reports might
be complicated by inclusion of T2D cases. The recent pub-
lication by Liu et al. [18] reported no signiﬁcant change in
IRβ levels in the brains of nondiabetic AD cases, but did not
report the status of IR activation.
This study was designed to investigate the contents of
IRβ and [Tyr1162/1163]-phosphorylated IRβ as surrogate
indices of, respectively, total IR contents and IR activation6 International Journal of Alzheimer’s Disease
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Figure 2: Total IRβ and [Tyr1162/1163]-phosphorylated IRβ contents in peripheral temporal muscle and in brain hippocampal formation
specimens as a function of CDR. Total insulin IRβ contents in temporal muscle (a) and in the hippocampal formation (c) were assessed
by western blot analysis using a commercial antibody that is selective for IRβ and is not cross-reactive with IGF-1Rβ. Contents of
[Tyr1162/1163]-phosphorylated IRβ in temporal muscle (b) and in the hippocampal formation (d) were assessed by a commercial ELISA
that is speciﬁc for [Tyr1162/1163]-phosphorylated IRβ, and is not cross-reactive with IGF-IRβ. In ((a) and (c)), total IRβ contents are
expressed relative to β-actin levels assessed on the same Western blot using a speciﬁc β-actin antibody (Sigma, MO). Inset: representative
western blot analysis of total IRβ and β-actin contents in muscle ((a), inset) and hippocampal formation ((c), inset) from CDR 0, 0.5, 1, 2,
and5cases.In((b)and(d)),[Tyr1162/1163]-phosphorylatedIRβ isexpressedrelativetototalproteincontents.In((a)–(d)),valuesrepresent
group mean ± SEM values. ANOVA; P = .976 and .478, respectively, for IRβ and [Tyr1162/1163]-phosphorylated IRβ in temporal muscle;
P = .220 and .425, respectively, for IRβ and [Tyr1162/1163]-phosphorylated IRβ in the hippocampal formation.
in the brains of nondiabetic AD cases as a function of AD
dementia and AD-type neuropathology. Among the non-
diabetic cases examined in this study, we found that total IRβ
contents in postmortem hippocampal specimens from cases
characterized by mild cognitive impairment (CDR 0.5), mild
AD dementia (CDR 1), moderate AD dementia (CDR 2) and
severe AD dementia (CDR 5) were comparable to levels that
were found in cognitive normal (CDR 0) control cases. Our
ﬁndings are consistent with observations by Moloney et al.
[23] and Liu et al. [18], who reported comparable levels of
total IRα and IRβ proteins in postmortem temporal cortex
specimens from severe AD and control cases. In addition
to total IRβ protein contents, evidence from our nondia-
betic cohort also revealed similar levels of [Tyr1162/1163]-
phosphorylated IRβ in hippocampal specimens from CDR
0.5, 1, 2, and 5 cases compared to control CDR 0 cases.International Journal of Alzheimer’s Disease 7
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Figure 3: Total IRβ and [Tyr1162/1163]-phosphorylated IRβ contents in the hippocampal formation are not correlated with the contents of
Aβ peptides. In ((a) and (b)), correlation analysis of total IRβ content with contents of Aβ1–42 (a) and Aβ1–40 (b) peptides in the hippocampal
formation. In ((c) and (d)), correlation analysis of [Tyr1162/1163]-phosphorylated IRβ contents with Aβ1–42 (c) and Aβ1–40 (d) peptides in
the hippocampal formation. In ((a)–(d)), solid line represents the best-ﬁt correlation between IRβ or [Tyr1162/1163]-phosphorylated IRβ
with β1–42 or Aβ1–40 peptides. Pearson correlation analysis; P = .205 and .271 for IRβ contents with Aβ1–42 and Aβ1–40,r e s p e c t i v e l y;P = .684
and .681 for [Tyr1162/1163]-phosphorylated IRβ contents with Aβ1–42 and Aβ1–40,r e s p e c t i v e l y .
Moreover, we found that the severity of amyloid and tau
AD-neuropathology among nondiabetic AD cases was not
correlated with the contents of either total IRβ or [Tyr1162/
1163]-phosphorylated IRβ in the hippocampal formation.
Collectively, our observations tentatively suggest that non-
diabetic sporadic AD is characterized by normal IR content
and IR activation in the brain. Interestingly, Moloney et al.
[23] observed aberrant subcellular distributions of IRα and
IRβ proteins among surviving neurons in brain specimens
from severe AD cases, without the consideration of the
diabetic/nondiabetic status of these cases. Future studies will
be necessary to examine whether nondiabetic CDR 0.5, 1, 2,
and 5 cases might also be characterized by similar aber-
rant subcellular distribution of IRα/β and [Tyr1162/1163]-
phosphorylated IRβ in the brain.
Activation of the IR leads to the modulation of a large
number of cellular signaling processes [42–44]. However,
many of these cellular signaling molecules such as Akt and
GSK3 α/β are also regulated by other signaling processes
[45–49]. For example, activation of IR or insulin-like growth
factor 1 receptor (IGF-1R) both lead to receptor-mediated
tyrosine phosphorylation of adaptor proteins such as insulin
receptorsubstrateproteinsthat,inturn,modulatetheactiva-
tionofAkt[45],GSK3[50,51],extracellularsignal-regulated
kinase (ERK) [52], and other signaling pathways. Accu-
mulating epidemiological and experimental evidence sug-
gests that impairments in select IR-associated cellular signal-
ingpathwaysintheADbrainmightmechanisticallypromote
the AD phenotype [2, 3, 6, 7, 14–17, 25]. Among cellular
processes that are typically associated with IR-signaling,
impaired GSK3 α/β function in the AD brain is considered
pivotal for the development of AD [24–26, 53].
Consistent with previous reports [24, 25], we observed
signiﬁcantly lower levels of total GSK3 α/β in brain spec-
imens from nondiabetic sporadic AD cases examined in
this study. Our observation is consistent with evidence
from Griﬃn et al. [25], which demonstrated increased
Akt activation coinciding with elevated levels of inactive8 International Journal of Alzheimer’s Disease
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Figure 4: Total IRβ and [Tyr1162/1163]-phosphorylated IRβ contents in the brain are not correlated with the severity of AD-type
neuropathology. AD-type neuritic plaque (NP) and neuroﬁbrillary tangle (NFT) neuropathology were assessed using CERAD rating scales.
In ((a) and (c)), correlation analysis of total IRβ content with NP (a) and NFT (c) neuropathology in the brain. In ((b) and (d)), correlation
analysis of [Tyr1162/1163]-phosphorylated IRβ contents with NP (b) and NFT (d) neuropathology. In ((a)–(d)), solid line represents the
best-ﬁt correlation between IRβ or [Tyr1162/1163]-phosphorylated IRβ with NP or NFT neuropathology. Pearson correlation analysis;
P = .749 and .516 for IRβ contents with NP and NFT neuropathology, respectively; P = .283 and .912 for [Tyr1162/1163]-phosphorylated
IRβ contents with NP and NFT neuropathology, respectively.
Ser9-phosphorylated GSK-3β in the temporal cortex of
AD cases. IR (as well as the IGF-1R) signaling pathways
are known to regulate Akt, GSK3 α/β and other sig-
nal transduction mediators, primarily by modulating the
phosphorylation status and thereby the activities of these
signal transduction components [50–52, 54]. Based on this
consideration and on our observation suggesting normal
IR contents and IR activation in brain specimens from our
study cohort, downregulation of total GSK3 α/β contents
in the brains of nondiabetic sporadic AD cases is likely
mediated by mechanisms independent of IR activation.
Additional studies will be necessary to clarify whether
there might be changes in the regulation of other IR-
associated cellular signaling mechanisms in the brains of
nondiabetic cases, and the mechanisms by which cellular
contents and activities of Akt, GSK3 α/β, and other IR
mediators might be modulated in the AD brain. None-
theless,consistentwitharecentreportbyMoloneyetal.[23],
our observation suggests that, in spite of our evidence sug-
gesting normal IR contents and IR activation, impaired IR
signaling mechanisms in the brains of nondiabetic sporadic
AD cases might contribute to the onset and/or progression
of AD dementia.
Numerous epidemiological studies have linked T2D with
an increased risk for AD [2, 3, 6, 7]. We [14] and others
[15] demonstrated that diet-induced T2D in the Tg2576
AD mouse model leads to the promotion of AD-type
amyloid neuropathology and cognitive deterioration, whichInternational Journal of Alzheimer’s Disease 9
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Figure 5: Reduced contents of total GSK3α and GSK3β in the hippocampal formation in AD brain specimens are not correlated with
[Tyr1162/1163]-phosphorylated IRβ. Total GSK3α and GSK3β contents in the hippocampal formation were assessed by Western blot
analysis. In ((a) and (b)), bar graphs represent mean ± SEM total GSK3α (a) and total GSK3β (b) contents (nonphosphorylated and
phosphorylated GSK3 α/β) in the hippocampal formation relative to β-actin as a function of Clinical Dementia Rating. ANOVA; P = .0111
and .0112,respectively,forGSK3αandGSK3βcontentsamongCDRgroups.One-tailedt-testincomparisontoCDR0:∗P<. 05; ∗∗P<. 005.
Inset:representativeWesternblotanalysisoftotalGSK3αandtotalGSK3β fromCDR0,0.5,1,2and5hippocampalformationspecimens.In
((c) and (d)), correlation analysis of GSK3α (c) and GSK3β (d) contents with respect to [Tyr1162/1163]-phosphorylated IRβ contents in the
hippocampal formation. Pearson correlation analysis; P = .318 and .308 for GSK3α and GSK3β contents with contents of [Tyr1162/1163]-
phosphorylated IRβ,r e s p e c t i v e l y .
arebothassociatedwithimpairedIRactivityandIRsignaling
the brain. While our present studies suggest the existence of
impaired IR signaling in the brains of nondiabetic sporadic
AD cases, a recent study by Liu et al. [18] suggests that AD
and T2D may induce impaired IR signaling in the brain via
diﬀerent mechanisms than those implicated in our studies,
and that the presence of T2D may exacerbate IR signaling
impairments in the AD brain.
There is an increasing eﬀo r tt od e v e l o pn o v e lA Dt h e r -
apeutics based on the promotion of IR-signaling processes
by either directly inducing IR activation (e.g., nasal insulin
inhalation [55–57]) or by applying insulin-sensitization
measures (e.g., PPARγ activators [41, 58, 59]) that stimulate
downstreamIR-signaling.Priorstudieshavenotyetexplored
thepotentialimpactofcomorbiddiabeticversusnondiabetic
conditionsontheregulationofIRactivationintheADbrain.
Results from our study demonstrating reduced contents of
total GSK3 α/β in the brains of nondiabetic sporadic AD
cases suggest that, even in the absence of comorbid diabetic
conditions, impaired downstream IR signaling processes in10 International Journal of Alzheimer’s Disease
the AD brain may contribute to the onset and/or progression
of AD phenotypes. This would support the application of
insulin-sensitization therapeutic strategies in nondiabetic,
sporadic AD. While accumulating experimental evidence
suggests that diabetic conditions could lead to reduced IR
activity in the brain [14, 15], our present study found no
detectable changes in IR activity in the brains of nondiabetic
sporadic AD cases. Based on this, we suggest that, in com-
parison to nondiabetic sporadic AD cases, sporadic AD
caseswithconcomitantdiabeticconditionsmayrespondbet-
ter to therapeutic strategies such as intranasal insulin admin-
istration that are designed to directly target IR in the brain.
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